Company: SNSE
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0000950170-25-053033
Chunk: 43

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 43
---
 2020. Mr. Craver began his career at PricewaterhouseCoopers in the health industries audit practice, primarily serving life science and biotech companies. Mr. Craver holds a M.S. in Accountancy from Stonehill College and is a Certified Public Accountant. Edward van der Horst, Ph.D. , age 52 Edward van der Horst, Ph.D. has served as our Chief Scientific Officer since December 2022. Dr. van der Horst previously served as our Senior Vice President of Biologics Discovery and Early Development from October 2021 to December 2022 and as our Vice President of Preclinical Development from September 2019 to October 2021. Prior to joining us, Dr. van der Horst served as Vice President, Discovery Biology & Preclinical Drug Development at Zenith Epigenetics Ltd., a clinical stage oncology company, from 2017 to August 2019. Prior to Zenith Epigenetics, from 2010 to 2017, he served in various roles at Igenica Biotherapeutics, Inc., an immunotherapy company, including as Senior Director of Preclinical Development. Dr. van der Horst attended the University of Dusseldorf, holds a M.Sc. in Chemistry from Ludwig-Maximilians-Universitat Munchen and a Ph.D. in Biochemistry and Molecular Biology from Max-Plank-Institute for Biochemistry. Stephanie Krebs , age 47 Stephanie Krebs has served as our Chief Business Officer since November 2023. Prior to joining us, Ms. Krebs served as Chief Business Officer at SNIPR Biome APS from March 2022 to October 2023, Vice President and Head of Business Development at Valo Health, Inc. from June 2021 to February 2022, Head of Severe Genetic Disease Business Development at Bluebird Bio, Inc. from September 2019 to May 2021, Vice President of Business Development at HotSpot Therapeutics, Inc. from August 2018 to August 2019, and as Vice President of Corporate Development at Swedish Orphan Biovitrum (Sobi) AB from October 2016 to July 2018. Ms. Krebs also worked at Biogen Inc. in various roles of increasing responsibility from July 2006 to October 2016. She holds a Bachelor of Science in Microbiology and Immunology from the University of Rochester, a Master of Science in Biotechnology from Johns Hopkins University and an